David Albala, MD, discusses the key advantages of utilizing PSMA-PET screening in clinical practice for patients with prostate cancer.
David Albala, MD, chief of urology, Crouse Hospital, discusses the key advantages of utilizing PSMA-PET screening in clinical practice for patients with prostate cancer.
The sensitivity and specificity of PSMA-PET scans are superior to that of current modalities used to identify prostate cancer, Albala says. These conventional imaging techniques, such as bone scans or CT scans, and the more recently developed fluciclovine (Axumin)-PET/CT scan have all contributed to advancements in this imaging technology.
Ultimately, PSMA-PET scans show promising diagnostic performance, and could completely change the current landscape of prostate cancer imaging. Moving forward, clinicians should aim to understand what this exciting new technology entails and consider how to best incorporate it into their current treatment strategies, Albala concludes.